Results 161 to 170 of about 7,612 (209)

Revolutionizing HER2-Positive Breast Cancer Treatment: Insights from the 47th San Antonio Breast Cancer Symposium on Trastuzumab Deruxtecan. [PDF]

Asian Pac J Cancer Prev
Negahi A, Negahban H, Sayyad S, Khosravi-Mashizi M, Alijanpour A, Neamatzadeh H.   +5 more
europepmc   +1 more source

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs. [PDF]

Cancer Metastasis Rev
Ostios-Garcia L, Pérez DM, Castelo B, Herradón NH, Zamora P, Feliu J, Espinosa E.   +6 more
europepmc   +1 more source

Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report. [PDF]

Thorac Cancer
Nishihara M, Shinno Y, Masui Y, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Ohe Y.   +10 more
europepmc   +1 more source

Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer. [PDF]

Breast Cancer Res Treat
Zelizer S, Gallagher GB, Gonen M, Dang C, Modi S, Chandarlapaty S, Drago JZ.   +6 more
europepmc   +1 more source

246 New platforms of immunoconjugates

European Journal of Cancer Supplements, 2010
openaire   +1 more source

Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer. [PDF]

Future Oncol
Shin J, Kim JY, Ahn HK, Ahn JS, Park YH.
europepmc   +1 more source

Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors. [PDF]

CPT Pharmacometrics Syst Pharmacol
Babel H, Brunsdon P, Engelhardt B, Schmitt V, Ratajczak C, Mensing S, Menon RM, Parikh A.   +7 more
europepmc   +1 more source

Revolutionizing cancer treatment: the rise of personalized immunotherapies. [PDF]

Discov Oncol
Fayyaz A, Haqqi A, Khan R, Irfan M, Khan K, Reiner Ž, Sharifi-Rad J, Calina D.   +7 more
europepmc   +1 more source

Polarity- and Sequence-Dependent Ionization of Therapeutic Antibody-siRNA Conjugates: Enabling Intact Multi-attribute Method for Comprehensive Characterization and Identity Release Assay. [PDF]

Anal Chem
Liu H, Veltri JL, Gough PC, Crowe SO, Davis E, Whitaker M, Buckley C, Lian ZJ.   +7 more
europepmc   +1 more source

Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer. [PDF]

Curr Oncol
Vida R, Bartoletti M, Lerda L, Corsetti S, Scalone S, Calabrò A, Caroli A, Rizzetto M, Zapelloni G, Caccin E, Fucina S, Bortolin G, Cecco S, Baldo P, Pignata S, Califano D, Canzonieri V, Ditto A, Puglisi F.   +18 more
europepmc   +1 more source